Overview
Background
Andrew Martin is inaugural Professor of Innovative Clinical Trials and leads the University of Queensland’s cLinical Trials cApability (ULTRA) program. Andrew was Professor in the biostatistics group at the NHMRC Clinical Trials Centre University of Sydney. He maintains that role in an honorary capacity since joining UQ. Prior to academia, Andrew held senior biostatistics roles within research-based pharmaceutical organisations (Pfizer and Roche).
Grants
Category 1: $14.3M Category 3: $131.8M
Grants: 2023 Clinical Trials and Cohort Studies Grant ID 2032441 ($1,362,000): P3BEP Trial - Accelerating First-Line Chemotherapy to Improve Cure Rates for Advanced Germ Cell Tumours; 2022 NHMRC Partnership Projects Grant 2015773 ($1,166,592): Strengthening healthcare systems with Patient Reported Outcome Measures (PROMs); 2020 CA ($600,000): Immuno-metabolic biomarkers for metastatic prostate cancer treatment response; 2018 MRFF Grant APP1170066 ($1,596,631): WHEAT Study on reducing NEC in preterm infants; 2018 CA Grant APP1158397 ($479,375): SCORE trial for shared colorectal cancer care; 2018 CA Grant APP1159837 ($600,000): P3BEP Trial for advanced germ cell tumours; 2018 NHMRC Project Grant APP1159787 ($1,587,163): BCG+MM Trial for bladder cancer; 2016 Victorian Cancer ($300,000): SCORE project on shared care of Colorectal cancer survivors; 2015 CA Priority-driven Collaborative Cancer Research Scheme ($443,307): LEAD - Lung cancer diagnostic and treatment pathways; 2015 NHMRC Project Grant 1108328 ($624,824): Oral Nicotinamide for skin cancer chemoprevention after Transplant; 2014 Co-funded Grant 1079794 ($597,095): Methoxyflurane to reduce discomfort of prostate biopsy; 2013 NHMRC Project Grant 1064121 ($880,425): CHEST Australia project for quicker primary care consultations in lung cancer; 2012 NHMRC Project Grant APP1047100 ($2,203,171): Bovine lactoferrin study on low birthweight infants; 2011 National Breast Cancer Foundation ($199,606): Physical well-being for metastatic breast cancer; 2011 NHMRC Project Grant 1028555 ($187,018): Evidence on reduced child obesity rates; 2011 NHMRC Project Grant 1026977 ($586,691): Oral nicotinamide for skin cancer prevention; 2011 Australasian College of Dermatologists grant ($25,000): Nicotinamide for non-melanoma skin cancer in renal transplant recipients; 2010 NHMRC Project Grant 1007628 ($369,208): NEU-HORIZONS study on riluzole for oxaliplatin neurotoxicity; 2010 NHMRC Project Grant 1003414 ($564,410): Phase II prostate cancer follow-up trial in primary care.
Statistical lead on the following projects receiving industry funding with USyd as administering institution: ENZARAD NCT02446444 ($12,178,000); ENZAMET NCT02446405 ($20,408,129); INTEGRATE ACTRN12612000239864 ($6,900,000); INTEGRATE IIa ACTRN12616000420448 ($22,264,248); INTEGRATE IIb NCT04879368 ($36,330,215); DASL-HiCaP NCT04136353 ($33,777,579).
Availability
- Professor Andrew Martin is:
- Available for supervision
Research impacts
Research Achievements and Collaborations: Has made original, innovative, and distinguished contributions to methodological research, as well as the design, conduct, analysis, interpretation, and dissemination of clinical research that has had an impact at an international level policy, practice, and subsequent research programs. Has been responsible for the provision of statistical leadership to collaborative trials groups to design, undertake, analyse, and report on clinical trials, as well as promoting investigator-initiated research activities. 2020-2024 Scopus/SciVal author publication metrics: FWCI of 5.21, 51% in top 10% most cited worldwide, 39% international collaboration 3,763 citations (10,934 overall). Received the 2020 ACTA (Australian Clinical Trials Alliance) Statistics in Trials Interest Group Excellence in Trial Statistics Award for ENZAMET Trial. Research funding in last 5 years: $3.1M category 1 and $76.7M category 3.
Contributions to the Field: Led methodological research with international impact. Examples in the last 5 years focus on the topic of changes to the design of ongoing trials. This work has been cited in the CONSERVE 2021 Statement (JAMA. 2021;326(3):257-265 FWCI 7.38; top 1% of general medical journals). Also co-published innovative method for appropriately adjusting estimates of effect obtained from trials that terminate early based on the results of an interim analysis (Statistical Methods in Medical Research – top 11% for statistics journals). Co-designed andled the statistical aspects of design, conduct, analysis, and interpretation of many trial. Two key examples in the last 5 years include ENZAMET and TheraP. (1) ENZAMET study selected for plenary presentation at ASCO (peak international clinical oncology conference attended by over 30,000 international delegates). Am second author for both main N Engl J Med paper (2019;381:121) (journal ranked top 1% general medicine), the quality of life J Clin Oncol paper (2022;40:837-46) (journal ranked top 2% cancer research), and the follow-up Lancet Oncol paper (2022;23:1389) (journal ranked top 1% cancer research). Results were used in support of successful registration of enzalutamide with US FDA in this indication and have been incorporated into US and European treatment guidelines. (2) TheraP evaluated efficacy of cutting-edge targeted radiopharmaceutical (Lu-PSMA) in advance prostate cancer that delivers radiation to cells expressing the prostate-specific membrane antigen. Selected for oral presentation at highly prestigious ASCO 2020 and ASCO GU 2021 conferences. Second senior author of The Lancet paper (2021;397:797) (journal ranked top 1% general medicine). Has led to 2 additional RCTs of Lu-PSMA that I co-designed. One (ENZA-p) was just published in Lancet Oncol (2024 Apr 12:S1470-2045(24)00135-9) (journal ranked top 1% cancer research).
Works
Search Professor Andrew Martin’s works on UQ eSpace
2023
Journal Article
Accuracy of oncologists' estimates of expected survival time in advanced cancer
Nahm, Sharon H., Martin, Andrew J., Clayton, Josephine M., Grimison, Peter, Moth, Erin B., Pavlakis, Nick, Sjoquist, Katrin, Smith-Uffen, Megan E. S., Tognela, Annette, Vasista, Anuradha, Stockler, Martin R. and Kiely, Belinda E. (2023). Accuracy of oncologists' estimates of expected survival time in advanced cancer. JNCI Cancer Spectrum, 7 (6) pkad094. doi: 10.1093/jncics/pkad094
2023
Journal Article
SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancer
Jefford, Michael, Emery, Jon D., James Martin, Andrew, De Abreu Lourenco, Richard, Lisy, Karolina, Grunfeld, Eva, Mohamed, Mustafa Abdi, King, Dorothy, Tebbutt, Niall C., Lee, Margaret, Mehrnejad, Ashkan, Burgess, Adele, Marker, Julie, Eggins, Renee, Carrello, Joseph, Thomas, Hayley and Schofield, Penelope (2023). SCORE: a randomised controlled trial evaluating shared care (general practitioner and oncologist) follow-up compared to usual oncologist follow-up for survivors of colorectal cancer. eClinicalMedicine, 66 102346, 1-11. doi: 10.1016/j.eclinm.2023.102346
2023
Conference Publication
Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304)
Horvath, L. G., Davis, I. D., Martin, A., Zielinski, R., Thomson, A., Tan, T. H., Sandhu, S. K., Reaume, M. N., Pook, D., Parnis, F., North, S., Marx, G. M., McCaffrey, J. A., McDermott, R. S., Lawrence, N., Frydenberg, M., Chowdhury, S., Chi, K. N. N., Stockler, M. R. and Sweeney, C. (2023). Effects of enzalutamide on overall survival plus /- early docetaxel in participants aged less than 70 yrs versus greater than or equal to 70 yrs in ENZAMET (ANZUP 1304). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.2742
2023
Conference Publication
Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901)
Emmett, L., Subramaniam, S., Crumbaker, M., Joshua, A. M., Weickhardt, A. J., Lee, S. T., Ng, S., Francis, R. J., Goh, J. C. H., Pattison, D. A., Tan, H., Kirkwood, I. D., Sandhu, S. K., Nguyen, A., Gedye, C., Rutherford, N., Hofman, M., Martin, A., Stockler, M. R. and Davis, I. D. (2023). Enzalutamide and 177Lu-PSMA-617 in poor-risk, metastatic, castration-resistant prostate cancer (mCRPC): A randomised, phase II trial: ENZA-p (ANZUP 1901). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.10.086
2023
Conference Publication
Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601)
Gedye, C., Harris, C. A., Stockler, M. R., Morris, M., Ferguson, T., Goh, J. C. H., Martin, A., Underhill, C. R., Pook, D., Krieger, L. E. M., Kichenadasse, G., Joshi, A. J., Subramaniam, S., Zebic, D. S., Zhang, A., Joshua, A. M., Toner, G. C., Vasey, P. A., Prithviraj, P. and Davis, I. D. (2023). Pembrolizumab and denosumab in clear cell renal cell carcinoma (ccRCC): A phase II trial (KeyPAD, ANZUP1601). Congress of the European-Society-for-Medical-Oncology (ESMO), Madrid Spain, Oct 20-24, 2023. AMSTERDAM: ELSEVIER. doi: 10.1016/j.annonc.2023.09.1116
2023
Journal Article
Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer
Sjoquist, Katrin M., Martin, Andrew, Pavlakis, Nick, Goldstein, David, Tsobanis, Eric, Moses, Daniel, Maher, Richard, Hague, Wendy, Gebski, Val, Stockler, Martin R. and Simes, R. John (2023). Value of central review of RECIST v1.1 outcomes in the AGITG INTEGRATE randomised phase 2 international trial for advanced oesophago-gastric cancer. Journal of Cancer Research and Clinical Oncology, 149 (8), 4959-4965. doi: 10.1007/s00432-022-04404-4
2023
Conference Publication
Effects of [<SUP>177</SUP>Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis
Soon, Yu Yang, Marschner, Ian, Hofman, Michael S., Emmett, Louise, Davis, Ian D., Stockler, Martin R. and Martin, Andrew James (2023). Effects of [177Lu] Lu-PSMA-617 on overall survival in TheraP versus VISION randomized trials: An exploratory analysis. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-06, 2023. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2023
Conference Publication
Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC)
Hayne, Dickon, Stockler, Martin R., Martin, Andrew James, McCombie, Steve P., Zebic, Danka Sinikovic, Bastick, Patricia A., Beardsley, Emma Kate, Frydenberg, Mark, Green, William, Grummet, Jeremy, Hawks, Cynthia, Ischia, Joseph, Mitterdorfer, Andrew, Patel, Manish, Roberts, Matthew, Sengupta, Shomik, Srivastav, Ratnesh Kumar, Redfern, Andrew David and Davis, Ian D. (2023). Adding mitomycin (MM) to bacillus Calmette-Guerin (BCG) as adjuvant intravesical therapy for high-risk, non-muscle-invasive urothelial bladder cancer (NMIBC). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins.
2023
Conference Publication
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)
Zebic, Danka Sinikovic, Ben Tran,, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago, IL USA, 2-6 June 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins.
2023
Conference Publication
An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs)
Zebic, Danka Sinikovic, Tran, Ben, Martin, Andrew James, Pashankar, Farzana D., Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Wyld, David, Lawrence, Nicola Jane, Stockler, Martin R., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Annual Meeting, Chicago, IL USA, 2-6 June 2023. Alexandria, VA USA: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.16_suppl.tps5102
2023
Conference Publication
SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors
Jefford, Michael, Emery, Jon D., Martin, Andrew James, Lourenco, Richard De Abreu, Lisy, Karolina, Mohamed, Mustafa Abdi, King, Dorothy, Tebbutt, Niall C., Lee, Margaret, Mehrnejad, Ashkan, Burgess, Adele, Marker, Julie, Eggins, Renee, Carrello, Joseph, Thomas, Hayley and Schofield, Penelope (2023). SCORE: A multisite randomised controlled trial evaluating shared care for colorectal cancer survivors. Annual Meeting of the American-Society-of-Clinical-Oncology (ASCO), Chicago Il, Jun 02-06, 2023. PHILADELPHIA: LIPPINCOTT WILLIAMS & WILKINS.
2023
Journal Article
Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial
Sweeney, Christopher J, Martin, Andrew J, Stockler, Martin R, Begbie, Stephen, Cheung, Leanna, Chi, Kim N, Chowdhury, Simon, Frydenberg, Mark, Horvath, Lisa G, Joshua, Anthony M, Lawrence, Nicola J, Marx, Gavin, McCaffrey, John, McDermott, Ray, McJannett, Margaret, North, Scott A, Parnis, Francis, Parulekar, Wendy, Pook, David W, Reaume, Martin Neil, Sandhu, Shahneen K, Tan, Alvin, Tan, Thean Hsiang, Thomson, Alastair, Vera-Badillo, Francisco, Williams, Scott G, Winter, Diana, Yip, Sonia, Zhang, Alison Y ... Thomas, Carys (2023). Testosterone suppression plus enzalutamide versus testosterone suppression plus standard antiandrogen therapy for metastatic hormone-sensitive prostate cancer (ENZAMET): an international, open-label, randomised, phase 3 trial. The Lancet Oncology, 24 (4), 323-334. doi: 10.1016/S1470-2045(23)00063-3
2023
Journal Article
Nicotinamide for skin-cancer chemoprevention in transplant recipients
Allen, Nicholas C., Martin, Andrew J., Snaidr, Victoria A., Eggins, Renee, Chong, Alvin H., Fernandéz-Peñas, Pablo, Gin, Douglas, Sidhu, Shireen, Paddon, Vanessa L., Banney, Leith A., Lim, Adrian, Upjohn, Edward, Schaider, Helmut, Ganhewa, Aparna D., Nguyen, Jennifer, Mckenzie, Catriona A., Prakash, Saurabh, Mclean, Catriona, Lochhead, Alistair, Ibbetson, Jan, Dettrick, Andrew, Landgren, Anthony, Allnutt, Katherine J., Allison, Clare, Davenport, Rachael B., Mumford, Blake P., Wong, Brittany, Stagg, Brendan, Tedman, Alexander ... Damian, Diona L. (2023). Nicotinamide for skin-cancer chemoprevention in transplant recipients. New England Journal of Medicine, 388 (9), 804-812. doi: 10.1056/NEJMoa2203086
2023
Journal Article
INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG)
Lam, Lyn Ley, Pavlakis, Nick, Shitara, Kohei, Sjoquist, Katrin M., Martin, Andrew J., Yip, Sonia, Kang, Yoon-Koo, Bang, Yung-Jue, Chen, Li-Tzong, Moehler, Markus, Bekaii-Saab, Tanios, Alcindor, Thierry, O’Callaghan, Christopher J., Tebbutt, Niall C., Hague, Wendy, Chan, Howard, Rha, Sun Young, Lee, Keun-Wook, Gebski, Val, Jaworski, Anthony, Zalcberg, John, Price, Timothy, Simes, John and Goldstein, David (2023). INTEGRATE II: randomised phase III controlled trials of regorafenib containing regimens versus standard of care in refractory Advanced Gastro-Oesophageal Cancer (AGOC): a study by the Australasian Gastro-Intestinal Trials Group (AGITG). BMC Cancer, 23 (1) 180, 1-12. doi: 10.1186/s12885-023-10642-7
2023
Conference Publication
P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs)
Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Tran, Ben, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J., Grimison, Peter S. and Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). P3BEP (ANZUP 1302): An international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediate- and poor-risk metastatic germ cell tumours (GCTs). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps431
2023
Conference Publication
Evolution:phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001)
Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Weickhardt, Andrew James, Lee, Sze Ting, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D. and Emmett, Louise (2023). Evolution:phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA617 in combination with ipilimumab and nivolumab for men with metastatic castrationresistant prostate cancer (mCRPC; ANZUP 2001). Genitourinary Cancers Symposium, Virtual, 16-18 February 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins.
2023
Conference Publication
Evolution: Phase II study of radionuclide <sup>177</sup>Lu-PSMA-617 therapy versus <sup>177</sup>Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001)
Sandhu, Shahneen, Subramaniam, Shalini, Hofman, Michael S., Stockler, Martin R., Martin, Andrew James, Pokorski, Izabella, Goh, Jeffrey C., Pattison, David A., Dhiantravan, Nattakorn, Gedye, Craig, Rutherford, Natalie K., Joshua, Anthony M., Tan, Thean Hsiang, Kirkwood, Ian D., Lee, Sze Ting, Weickhardt, Andrew James, Alipour, Ramin, Nguyen, Andrew, Davis, Ian D., Emmett, Louise and The Australian and New Zealand Urogenital and Prostate Cancer Trials Group (ANZUP) (2023). Evolution: Phase II study of radionuclide 177Lu-PSMA-617 therapy versus 177Lu-PSMA-617 in combination with ipilimumab and nivolumab for men with metastatic castration-resistant prostate cancer (mCRPC; ANZUP 2001). 2023 ASCO Genitourinary Cancers Symposium, San Francisco, CA United States, 16-18 February 2023. Alexandria, VA United States: American Society of Clinical Oncology. doi: 10.1200/jco.2023.41.6_suppl.tps271
2023
Conference Publication
P3BEP (ANZUP 1302): an international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs)
Zebic, Danka, Stockler, Martin R., Martin, Andrew James, Pashankar, Farzana D., Ben Tran,, Mazhar, Danish, Huddart, Robert A., Wheater, Matthew, Walpole, Euan Thomas, Dunwoodie, Elaine, Feldman, Darren R., Birtle, Alison Jane, Stevanovic, Amanda Gwendolyn, Wyld, David, Hanning, Fritha J. and Grimison, Peter S. (2023). P3BEP (ANZUP 1302): an international randomized phase 3 trial of accelerated versus standard BEP chemotherapy for male and female adults and children with intermediateand poor-risk metastatic germ cell tumours (GCTs). Genitourinary Cancers Symposium, Virtual, 16-18 February 2023. Philadelphia, PA USA: Lippincott Williams & Wilkins.
2023
Journal Article
Evaluation of 177Lu-PSMA SPECT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN)
Pathmanandavel, Sarennya, Crumbaker, Megan, Ho, Bao, Yam, Andrew O., Wilson, Peter, Niman, Remy, Ayers, Maria, Sharma, Shikha, Hickey, Adam, Eu, Peter, Stockler, Martin, Martin, Andrew J., Joshua, Anthony M., Nguyen, Andrew and Emmett, Louise (2023). Evaluation of 177Lu-PSMA SPECT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN). Journal of Nuclear Medicine, 64 (2), 221-226. doi: 10.2967/jnumed.122.264398
2023
Journal Article
Nicotinamide for Skin-Cancer Chemoprevention in Transplantation
Schmults, Chrysalyne D., Jambusaria-Pahlajani, Anokhi, Ruiz, Emily, Trepanowski, Nicole, Kim, Daniel Y., Hartman, Rebecca I., Allen, Nicholas C., Martin, Andrew J. and Damian, Diona L. (2023). Nicotinamide for Skin-Cancer Chemoprevention in Transplantation. New England Journal of Medicine, 388 (26), 2493-2495. doi: 10.1056/NEJMc2303841
Funding
Current funding
Supervision
Availability
- Professor Andrew Martin is:
- Available for supervision
Before you email them, read our advice on how to contact a supervisor.
Supervision history
Current supervision
-
Doctor Philosophy
Advanced methods for biomarker informed endometrial cancer
Associate Advisor
Other advisors: Dr Eva Baxter, Dr Zoe West, Professor Andreas Obermair
Media
Enquiries
For media enquiries about Professor Andrew Martin's areas of expertise, story ideas and help finding experts, contact our Media team: